Sort   by:  
 Page size 
MetabolomicsPharmacological Targeting of ALDH1a2 in Dendritic Cells Enhances Antigen Presentation, T Cell Activation and Anti-tumor immunity
Dendritic cell (DC) vaccines have been proposed as cancer immunotherapies due to their role as crucial antigen-presenting cells that regulate T cell functions. Despite considerable efforts to optimize ex vivo priming of DCs, DC vaccines have rarely been successful, suggesting the presence of unknown...
2025-11-03 | MTBLS10389 | MetaboLights
MetabolomicsTargeting secreted MDK-mediated tryptophan/kynurenine metabolism enhances DLL3 CAR T therapy for SCLC

Small cell lung cancer (SCLC) exhibits profound immunometabolic suppression that impairs antigen presentation and constrains immunotherapy efficacy. Through integrated multi-omics analyses of primary human SCLC tumors, we identified midkine (MDK) as a dominant tumor-secreted driver of immune evas...

2026-03-23 | MTBLS14116 | MetaboLights
MetabolomicsTumor-derived L-arginine acts as a metabolic checkpoint to sustain CAR T cell anti-tumor memory

Metabolic competition within the tumor microenvironment (TME) severely impairs the efficacy and persistence of chimeric antigen receptor (CAR) T cells in solid tumors. While targeting tumor metabolism is a promising therapeutic avenue, its precise implementation remains a challenge. Here, we disc...

2026-10-23 | MTBLS14035 | MetaboLights
MetabolomicsTargeting GSTZ1 sensitizes KRASG12C-mutant lung cancer cells by overcoming glutathione and glycolysis pathway rewiring

KRAS mutations are prevalent in lung cancer, but KRAS G12C inhibitors exhibit limited efficacy, partly due to metabolic adaptations, such as enhanced glutathione metabolism and increased glycolysis. Glutathione S-Transferase Zeta 1 (GSTZ1) is a metabolic enzyme that regulates cell metabolism. How...

2026-05-15 | MTBLS12791 | MetaboLights
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
MetabolomicsActivated ATF6α is a hepatic tumor driver restricting immunosurveillance

Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related mortality with limited therapies. While endoplasmic reticulum (ER)-stress and the unfolded protein response (UPR) are implicated in HCC, the involvement of the UPR-transducer activating transcription factor 6 alpha (ATF...

2025-11-17 | MTBLS13241 | MetaboLights
MetabolomicsTargeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights
MetabolomicsFunctional targeting of PTTG1 in pericytes restores vascular integrity in diabetic retina
Pericyte loss is an early and critical event in the pathogenesis of diabetic retinopathy (DR), yet the molecular mechanisms underlying pericyte dysfunction remain incompletely understood. Using single-cell RNA sequencing, we generated a retinal cellular overview comprising 37,982 cells from diabetic...
2026-03-30 | MTBLS14184 | MetaboLights
MetabolomicsFunctional targeting of PTTG1 in pericytes restores vascular integrity in diabetic retina

Pericyte loss is an early and critical event in the pathogenesis of diabetic retinopathy (DR), yet the molecular mechanisms underlying pericyte dysfunction remain incompletely understood. Using single-cell RNA sequencing, we generated a retinal cellular overview comprising 18,926 cells from...

2026-03-27 | MTBLS13544 | MetaboLights
MetabolomicsSingle-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance
Multi-drug resistance (MDR) is an almost inevitable end point of cancer therapy, driving rapid tumor progression, yet its evolutionary logic remains unclear because MDR tumors are rarely resected. Using paired therapy-naive and MDR melanoma specimens from a clinical trial, integrated with single-cel...
2027-08-13 | MTBLS15322 | MetaboLights
Sort   by:  
 Page size